OPKO Health, Inc. (OPK)
| Market Cap | 3.10B |
| Revenue (ttm) | 1.44B |
| Net Income (ttm) | 30.59M |
| Shares Out | 640.66M |
| EPS (ttm) | 0.05 |
| PE Ratio | 86.15 |
| Forward PE | 30.03 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 4 |
| Last Price | $4.14 |
| Previous Close | $4.32 |
| Change ($) | -0.19 |
| Change (%) | -4.28% |
| Day's Open | 4.30 |
| Day's Range | 4.08 - 4.53 |
| Day's Volume | 9,781,281 |
| 52-Week Range | 1.12 - 6.47 |
These seven penny stocks are most likely to push through the $5 mark having built a significant head of steam in the past year. The post 7 Penny Stocks Close To Busting Through the $5 Mark app...
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Returning buyers and chief executives were among the insiders making purchases th...
NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the European Medicines Agency (EMA) has validated for review the Marketing Au...
With the crazy bullishness in the market, you can't find too many discounted plays. However, these sleeper stocks might just give your portfolio the kickstart it needs in 2021.
NEW YORK, Feb. 22, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), announced its participation in the NY Forward Rapid Testing Program and opened eig...
OPKO Health's (OPK) fourth-quarter results benefit from strength in diagnostics.
Opko Health Inc (NASDAQ: OPK) reported Q4 results that came in above expectations with EPS of $0.05 beating the estimate of $0.04 and sales of $494.6 million higher than the consensus of $443....
Hint: Investors are more focused on concerns about the future than successes of the recent past.
OPKO Health (OPK) delivered earnings and revenue surprises of 25.00% and 13.41%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of OPKO Health (NASDAQ:OPK) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 266.67% over the past year to $0.05, which beat...
OPKO Health's (OPK) fourth-quarter results are likely to reflect solid performance from Services and Products segment and RAYALDEE.
MIAMI, Feb. 03, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2020, as well as discuss financ...
The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causin...
Penny stocks are cheap for a reason, as there are obvious flaws. However, with those flows comes opportunity.
OPKO Health's (OPK) BioReference introduces an in-home, fully-integrated digital platform providing access to diagnostic services.
OPKO Health, Inc. (OPK) CEO Phil Frost Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)
ELMWOOD PARK, N.J., Jan. 13, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today introduced Scarlet Health™, an in-home, fully integrated digital p...
Calls on Analysts and Stockholders Attending J.P. Morgan's Healthcare Conference to Determine Whether Management Disputes our Analysis and Stands by Original 4Q'20 Guidance Calls on Analysts a...
OPKO Health (OPK) closed the most recent trading day at $4.48, moving +1.82% from the previous trading session.
It's the perfect time for a wealthy CEO to ride off into the sunset.
MIAMI, Jan. 05, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the 39th Annual J.P. Morgan Healthcare Conference being held v...
OPKO Health's (OPK) BioReference commences mandatory, large-scale COVID-19 testing programs for fans for AFC Division Wild Card playoff game.
ELMWOOD PARK, N.J., Jan. 4, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced the results of COVID-19 molecular PCR tests for public s...
NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the US Food and Drug Administration (FDA) has accepted for filing the initial...
OPKO Health has been experiencing an historic year in terms of business achievements, execution, and public recognition. The current Opko share price has been trading at extremely depressed le...
These interesting low-cost stocks have the opportunity to grow.
MIAMI, Dec. 21, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Roger Medel, M.D. as an independent member of its Board of Directors, effective Dece...
Having college and professional athletes play sports during a pandemic can create logistics problems with social distancing and COVID-19 testing. Two small cap companies have won contracts to ...
Rumors of a potential sale of the company's growth hormone royalty stream excited investors.
OPKO Health, Inc. (OPK) Management Presents at Jefferies 2020 Virtual London Healthcare Conference (Transcript)
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider bu...
MIAMI, Nov. 11, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in three upcoming virtual investor conferences.
Patient investors could double their money in these two stocks that the market has temporarily cast aside.
OPKO Health's (OPK) third-quarter results benefit from increase in RAYALDEE prescriptions.
The healthcare company reported Q3 results that some didn't think were strong enough.
OPKO Health, Inc. (OPK) CEO Phil Frost on Q3 2020 Results - Earnings Call Transcript
OPKO Health (OPK) delivered earnings and revenue surprises of 0.00% and 14.07%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of OPKO Health (NASDAQ:OPK) fell 6.4% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 144.44% year over year to $0.04, which ...
OPKO Health's (OPK) third-quarter results are likely to reflect solid performance from Products segment and RAYALDEE.
In the latest trading session, OPKO Health (OPK) closed at $4.30, marking a +0.7% move from the previous day.
OPKO Health's (OPK) BioReference Laboratories' new multiplex test can differentiate between COVID-19 and Influenza infections with a single sample.
OPKO Health (OPK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Despite high-profile agreements to provide coronavirus testing, this small-cap company might not pass the test in the long term.
One is producing large numbers of COVID-19 diagnostic tests; the other may be among the first companies to get a coronavirus vaccine approved.
Successful partnerships with major sports leagues and updated guidance may mean coronavirus testing is here to stay.
MIAMI, Oct. 13, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended September 30, 2020, as well as discuss finan...
ELMWOOD PARK, N.J., Oct. 9, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ :OPK), today announced the beginning of its COVID-19 testing program for New Yo...
SEATTLE, Oct. 8, 2020 /PRNewswire/ -- UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF FLORIDA Case No. 1:18-cv-23786-MARTINEZ-OTAZO-REYES CHARLES STEINBERG, individually and on Behalf of All...
NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study eva...
About OPK
OPKO Health, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and go... [Read more...]
| Industry Diagnostics & Research | IPO Date Nov 2, 1995 |
| CEO Phillip Frost | Employees 5,269 |
| Stock Exchange NASDAQ | Ticker Symbol OPK |
Analyst Forecasts
According to 5 analysts, the average rating for OPKO Health stock is "Buy." The 12-month stock price forecast is 8.25, which is an increase of 99.52% from the latest price.